This Article Full Text Full Text (PDF) CME: Take the course for this article: Circulation: April 21, 2009, Volume 119, Number 15 Data Supplement All Versions of this Article: 119/15/2103    most recent CIRCULATIONAHA.108.843219v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Drew, B. G. Articles by Kingwell, B. A. Search for Related Content PubMed PubMed Citation Articles by Drew, B. G. Articles by Kingwell, B. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Diabetes Hazardous Substances DB GLUCOSE PHENFORMIN Related Collections Energy metabolism Type 2 diabetes Lipid and lipoprotein metabolism Related Article

(Circulation. 2009;119:2103-2111.)
© 2009 American Heart Association, Inc.

Vascular Medicine

High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus

Brian G. Drew, PhD; Stephen J. Duffy, FRACP, PhD; Melissa F. Formosa, BSc; Alaina K. Natoli, BSc; Darren C. Henstridge, PhD; Sally A. Penfold, BSc; Walter G. Thomas, PhD; Nigora Mukhamedova, PhD; Barbora de Courten, MD, PhD; Josephine M. Forbes, PhD; Felicia Y. Yap, BSc; David M. Kaye, FRACP, PhD; Gerrit van Hall, PhD; Mark A. Febbraio, PhD; Bruce E. Kemp, PhD; Dmitri Sviridov, PhD; Gregory R. Steinberg, PhD; Bronwyn A. Kingwell, PhD

From Baker IDI Heart and Diabetes Institute, Melbourne, Australia (B.G.D., S.J.D., M.F.F., A.K.N., D.C.H., S.A.P., W.G.T., N.M., B.d.C., J.M.F., F.Y.Y., D.M.K., M.A.F., D.S., B.A.K.); Department of Medicine, Monash University, Clayton, Australia (B.G.D., D.C.H.); Copenhagen Muscle Research Centre, Copenhagen, Denmark (G.v.H.); St Vincent’s Institute of Medical Research and Department of Medicine, Fitzroy, Australia (B.E.K., G.R.S.); and Commonwealth Scientific and Industrial Research Organization, Molecular and Health Technologies, Parkville, Australia (B.E.K.).

Correspondence to Dr Bronwyn A. Kingwell, Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Rd Central, Melbourne, Australia, 8008. E-mail bronwyn.kingwell{at}bakeridi.edu.au

Received December 10, 2008; accepted February 11, 2009.

Background— Low plasma high-density lipoprotein (HDL) is associated with elevated cardiovascular risk and aspects of the metabolic syndrome. We hypothesized that HDL modulates glucose metabolism via elevation of plasma insulin and through activation of the key metabolic regulatory enzyme, AMP-activated protein kinase, in skeletal muscle.

Methods and Results— Thirteen patients with type 2 diabetes mellitus received both intravenous reconstituted HDL (rHDL: 80 mg/kg over 4 hours) and placebo on separate days in a double-blind, placebo-controlled crossover study. A greater fall in plasma glucose from baseline occurred during rHDL than during placebo (at 4 hours rHDL=–2.6±0.4; placebo=–2.1±0.3mmol/L; P=0.018). rHDL increased plasma insulin (at 4 hours rHDL=3.4±10.0; placebo= –19.2±7.4 pmol/L; P=0.034) and also the homeostasis model assessment β-cell function index (at 4 hours rHDL=18.9±5.9; placebo=8.6±4.4%; P=0.025). Acetyl-CoA carboxylase β phosphorylation in skeletal muscle biopsies was increased by 1.7±0.3-fold after rHDL, indicating activation of the AMP-activated protein kinase pathway. Both HDL and apolipoprotein AI increased glucose uptake (by 177±12% and 144±18%, respectively; P<0.05 for both) in primary human skeletal muscle cell cultures established from patients with type 2 diabetes mellitus (n=5). The mechanism is demonstrated to include stimulation of the ATP-binding cassette transporter A1 with subsequent activation of the calcium/calmodulin-dependent protein kinase kinase and the AMP-activated protein kinase pathway.

Conclusions— rHDL reduced plasma glucose in patients with type 2 diabetes mellitus by increasing plasma insulin and activating AMP-activated protein kinase in skeletal muscle. These findings suggest a role for HDL-raising therapies beyond atherosclerosis to address type 2 diabetes mellitus.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2009 119: 2017-2019. [Extract] [Full Text]

This article has been cited by other articles:

				M. Navab, G.M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman HDL as a Biomarker, Potential Therapeutic Target, and Therapy Diabetes, December 1, 2009; 58(12): 2711 - 2717. [Full Text] [PDF]

				A. C. Calkin, B. G. Drew, A. Ono, S. J. Duffy, M. V. Gordon, S. M. Schoenwaelder, D. Sviridov, M. E. Cooper, B. A. Kingwell, and S. P. Jackson Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux Circulation, November 24, 2009; 120(21): 2095 - 2104. [Abstract] [Full Text] [PDF]

				J. Petremand, N. Bulat, A.-C. Butty, C. Poussin, S. Rutti, K. Au, S. Ghosh, V. Mooser, B. Thorens, J.-Y. Yang, et al. Involvement of 4E-BP1 in the Protection Induced by HDLs on Pancreatic {beta}-Cells Mol. Endocrinol., October 1, 2009; 23(10): 1572 - 1586. [Abstract] [Full Text] [PDF]